AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) reported insider trading activity through a Form 4 filing for director Pamela Ann Connealy. On June 24, 2025, Connealy received two equity awards:

  • 12,422 Restricted Stock Units (RSUs) with zero exercise price, bringing her total direct ownership to 33,711 shares
  • 36,797 Stock Options with an exercise price of $3.22, expiring June 24, 2035

Both awards vest in a single installment at the earlier of: (1) one-year anniversary of the grant date, or (2) the 2026 Annual Meeting of Stockholders, subject to continuous service. The transaction was executed pursuant to the company's director compensation program, with the filing submitted by Andrew Taylor as attorney-in-fact on June 26, 2025.

Orchestra BioMed Holdings (OBIO) ha comunicato un'attività di insider trading tramite una dichiarazione Form 4 relativa alla direttrice Pamela Ann Connealy. Il 24 giugno 2025, Connealy ha ricevuto due premi azionari:

  • 12.422 Unità Azionarie Vincolate (RSU) con prezzo di esercizio pari a zero, portando la sua proprietà diretta totale a 33.711 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$, con scadenza il 24 giugno 2035

Entrambi i premi maturano in un'unica tranche al verificarsi della prima delle seguenti condizioni: (1) il primo anniversario della data di concessione, oppure (2) l'Assemblea Annuale degli Azionisti del 2026, subordinati alla continuità del servizio. La transazione è stata effettuata in conformità al programma di compensazione per i direttori della società, con la dichiarazione presentata da Andrew Taylor in qualità di procuratore il 26 giugno 2025.

Orchestra BioMed Holdings (OBIO) reportó una actividad de operaciones internas mediante una presentación del Formulario 4 para la directora Pamela Ann Connealy. El 24 de junio de 2025, Connealy recibió dos premios en acciones:

  • 12,422 Unidades Restringidas de Acciones (RSUs) sin precio de ejercicio, aumentando su propiedad directa total a 33,711 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22, que expiran el 24 de junio de 2035

Ambos premios se consolidan en un solo pago al cumplirse la primera de las siguientes condiciones: (1) el primer aniversario de la fecha de concesión, o (2) la Reunión Anual de Accionistas de 2026, sujeto a servicio continuo. La transacción se realizó conforme al programa de compensación para directores de la empresa, con la presentación realizada por Andrew Taylor como apoderado el 26 de junio de 2025.

Orchestra BioMed Holdings (OBIO)ëŠ� ì´ì‚¬ Pamela Ann Connealyì—� ê´€í•� ë‚´ë¶€ìž� 거래 활ë™ì� Form 4 신고서를 통해 보고했습니다. 2025ë…� 6ì›� 24ì�, ConnealyëŠ� ë‘� 가지 ì£¼ì‹ ë³´ìƒì� 받았습니ë‹�:

  • 12,422 제한 ì£¼ì‹ ë‹¨ìœ„(RSU)ë¡� í–‰ì‚¬ê°€ê²©ì´ ì—†ìœ¼ë©�, 그녀ì� ì§ì ‘ 소유 ì£¼ì‹ ì´ìˆ˜ëŠ� 33,711주가 ë˜ì—ˆìŠµë‹ˆë‹�
  • 36,797 ì£¼ì‹ ë§¤ìˆ˜ì„ íƒê¶�으로 í–‰ì‚¬ê°€ê²©ì€ $3.22ì´ë©°, 만료ì¼ì€ 2035ë…� 6ì›� 24ì¼ìž…니다

ë‘� ë³´ìƒ ëª¨ë‘ ë‹¤ìŒ ì¤� 빠른 시ì ì—� ë‹¨ì¼ ë¶„í• ë¡� 확정ë˜ë©°: (1) 부여ì¼ë¡œë¶€í„� 1주년, ë˜ëŠ” (2) 2026ë…� 주주ì´íšŒì´ë©°, ì§€ì†ì ì� 근무가 조건입니ë‹�. ì� 거래ëŠ� 회사ì� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ ì´ë£¨ì–´ì¡Œìœ¼ë©°, 2025ë…� 6ì›� 26ì� Andrew Taylorê°€ ëŒ€ë¦¬ì¸ ìžê²©ìœ¼ë¡œ 신고서를 제출했습니다.

Orchestra BioMed Holdings (OBIO) a déclaré une activité d’initié via un dépôt de formulaire 4 concernant la directrice Pamela Ann Connealy. Le 24 juin 2025, Connealy a reçu deux attributions d’actions :

  • 12 422 unités d’actions restreintes (RSU) sans prix d’exercice, portant sa détention directe totale à 33 711 actions
  • 36 797 options d’achat d’actions avec un prix d’exercice de 3,22 $, expirant le 24 juin 2035

Les deux attributions seront acquises en une seule fois à la première des dates suivantes : (1) le premier anniversaire de la date d’attribution, ou (2) l’assemblée générale annuelle des actionnaires de 2026, sous réserve d’un service continu. La transaction a été réalisée conformément au programme de rémunération des administrateurs de la société, le dépôt ayant été soumis par Andrew Taylor en tant que mandataire le 26 juin 2025.

Orchestra BioMed Holdings (OBIO) meldete Insiderhandel-Aktivitäten durch eine Form 4-Einreichung für die Direktorin Pamela Ann Connealy. Am 24. Juni 2025 erhielt Connealy zwei Aktienzuteilungen:

  • 12.422 Restricted Stock Units (RSUs) ohne Ausübungspreis, wodurch ihr direkter Gesamtbesitz auf 33.711 Aktien anstieg
  • 36.797 Aktienoptionen mit einem Ausübungspreis von 3,22 $, die am 24. Juni 2035 verfallen

Beide Zuteilungen werden in einer einzigen Tranche fällig, und zwar zu dem früheren Zeitpunkt von: (1) dem einjährigen Jubiläum des Gewährungsdatums oder (2) der Hauptversammlung 2026, vorbehaltlich ununterbrochener Dienstzeit. Die Transaktion wurde im Rahmen des Vergütungsprogramms für Direktoren des Unternehmens durchgeführt, wobei die Einreichung am 26. Juni 2025 von Andrew Taylor als Bevollmächtigter vorgenommen wurde.

Positive
  • None.
Negative
  • None.

Orchestra BioMed Holdings (OBIO) ha comunicato un'attività di insider trading tramite una dichiarazione Form 4 relativa alla direttrice Pamela Ann Connealy. Il 24 giugno 2025, Connealy ha ricevuto due premi azionari:

  • 12.422 Unità Azionarie Vincolate (RSU) con prezzo di esercizio pari a zero, portando la sua proprietà diretta totale a 33.711 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$, con scadenza il 24 giugno 2035

Entrambi i premi maturano in un'unica tranche al verificarsi della prima delle seguenti condizioni: (1) il primo anniversario della data di concessione, oppure (2) l'Assemblea Annuale degli Azionisti del 2026, subordinati alla continuità del servizio. La transazione è stata effettuata in conformità al programma di compensazione per i direttori della società, con la dichiarazione presentata da Andrew Taylor in qualità di procuratore il 26 giugno 2025.

Orchestra BioMed Holdings (OBIO) reportó una actividad de operaciones internas mediante una presentación del Formulario 4 para la directora Pamela Ann Connealy. El 24 de junio de 2025, Connealy recibió dos premios en acciones:

  • 12,422 Unidades Restringidas de Acciones (RSUs) sin precio de ejercicio, aumentando su propiedad directa total a 33,711 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22, que expiran el 24 de junio de 2035

Ambos premios se consolidan en un solo pago al cumplirse la primera de las siguientes condiciones: (1) el primer aniversario de la fecha de concesión, o (2) la Reunión Anual de Accionistas de 2026, sujeto a servicio continuo. La transacción se realizó conforme al programa de compensación para directores de la empresa, con la presentación realizada por Andrew Taylor como apoderado el 26 de junio de 2025.

Orchestra BioMed Holdings (OBIO)ëŠ� ì´ì‚¬ Pamela Ann Connealyì—� ê´€í•� ë‚´ë¶€ìž� 거래 활ë™ì� Form 4 신고서를 통해 보고했습니다. 2025ë…� 6ì›� 24ì�, ConnealyëŠ� ë‘� 가지 ì£¼ì‹ ë³´ìƒì� 받았습니ë‹�:

  • 12,422 제한 ì£¼ì‹ ë‹¨ìœ„(RSU)ë¡� í–‰ì‚¬ê°€ê²©ì´ ì—†ìœ¼ë©�, 그녀ì� ì§ì ‘ 소유 ì£¼ì‹ ì´ìˆ˜ëŠ� 33,711주가 ë˜ì—ˆìŠµë‹ˆë‹�
  • 36,797 ì£¼ì‹ ë§¤ìˆ˜ì„ íƒê¶�으로 í–‰ì‚¬ê°€ê²©ì€ $3.22ì´ë©°, 만료ì¼ì€ 2035ë…� 6ì›� 24ì¼ìž…니다

ë‘� ë³´ìƒ ëª¨ë‘ ë‹¤ìŒ ì¤� 빠른 시ì ì—� ë‹¨ì¼ ë¶„í• ë¡� 확정ë˜ë©°: (1) 부여ì¼ë¡œë¶€í„� 1주년, ë˜ëŠ” (2) 2026ë…� 주주ì´íšŒì´ë©°, ì§€ì†ì ì� 근무가 조건입니ë‹�. ì� 거래ëŠ� 회사ì� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ ì´ë£¨ì–´ì¡Œìœ¼ë©°, 2025ë…� 6ì›� 26ì� Andrew Taylorê°€ ëŒ€ë¦¬ì¸ ìžê²©ìœ¼ë¡œ 신고서를 제출했습니다.

Orchestra BioMed Holdings (OBIO) a déclaré une activité d’initié via un dépôt de formulaire 4 concernant la directrice Pamela Ann Connealy. Le 24 juin 2025, Connealy a reçu deux attributions d’actions :

  • 12 422 unités d’actions restreintes (RSU) sans prix d’exercice, portant sa détention directe totale à 33 711 actions
  • 36 797 options d’achat d’actions avec un prix d’exercice de 3,22 $, expirant le 24 juin 2035

Les deux attributions seront acquises en une seule fois à la première des dates suivantes : (1) le premier anniversaire de la date d’attribution, ou (2) l’assemblée générale annuelle des actionnaires de 2026, sous réserve d’un service continu. La transaction a été réalisée conformément au programme de rémunération des administrateurs de la société, le dépôt ayant été soumis par Andrew Taylor en tant que mandataire le 26 juin 2025.

Orchestra BioMed Holdings (OBIO) meldete Insiderhandel-Aktivitäten durch eine Form 4-Einreichung für die Direktorin Pamela Ann Connealy. Am 24. Juni 2025 erhielt Connealy zwei Aktienzuteilungen:

  • 12.422 Restricted Stock Units (RSUs) ohne Ausübungspreis, wodurch ihr direkter Gesamtbesitz auf 33.711 Aktien anstieg
  • 36.797 Aktienoptionen mit einem Ausübungspreis von 3,22 $, die am 24. Juni 2035 verfallen

Beide Zuteilungen werden in einer einzigen Tranche fällig, und zwar zu dem früheren Zeitpunkt von: (1) dem einjährigen Jubiläum des Gewährungsdatums oder (2) der Hauptversammlung 2026, vorbehaltlich ununterbrochener Dienstzeit. Die Transaktion wurde im Rahmen des Vergütungsprogramms für Direktoren des Unternehmens durchgeführt, wobei die Einreichung am 26. Juni 2025 von Andrew Taylor als Bevollmächtigter vorgenommen wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Connealy Pamela Ann

(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE

(Street)
NEW YORK PA 18938

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 06/24/2025 A 12,422(1) A $0 33,711 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.22 06/24/2025 A 36,797 (2) 06/24/2035 Common Stock 36,797 $0 36,797 D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
2. The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
/s/ Andrew Taylor, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at OBIO on June 24, 2025?

Director Pamela Ann Connealy received two equity awards: 12,422 restricted stock units (RSUs) and 36,797 stock options with an exercise price of $3.22. Both awards were granted on June 24, 2025.

What is the vesting schedule for OBIO director Pamela Connealy's June 2025 stock awards?

Both the RSUs and stock options will vest in one installment on the earlier of: (1) the one-year anniversary of the grant date (June 24, 2026) or (2) the date of OBIO's 2026 Annual Meeting of Stockholders, subject to continuous service.

How many shares of OBIO does Pamela Connealy own after the June 2025 transaction?

Following the transaction, Pamela Connealy directly owns 33,711 shares of OBIO common stock, plus 36,797 unvested stock options and 12,422 unvested RSUs.

What is the exercise price of OBIO stock options granted to director Connealy in June 2025?

The stock options were granted with an exercise price of $3.22 per share and have an expiration date of June 24, 2035.

When do Pamela Connealy's OBIO stock options expire?

The stock options granted to Pamela Connealy on June 24, 2025, expire on June 24, 2035, giving them a 10-year term from the grant date.
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

OBIO Latest News

OBIO Latest SEC Filings

OBIO Stock Data

119.54M
25.36M
21.82%
55.5%
1.39%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE